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Abstract  
Introduction: Patients with multiple tumors represent a segment of the cancer survivor population affected more 
than once by cancer, the phenomenon is still rare. 
Case presentation: In this report we present a patient who developed primary bladder urethral carcinoma with 
synchronous prostatic adenocarcinoma and metachronous papillary thyroid carcinoma where diagnosed within 
nine month period. There was no clear risk factors could explain this combination except smoking history. 
Conclusion: The diagnosis of cancer should not exclude the existence of other concomitant malignancies. This 
combination of multiple primary carcinomas, to our knowledge, has never been reported in the literature. 
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Introduction 
Multiple primary cancers (MPCs) generally fall into two categories; synchronous, in which the second 
cancers occur simultaneously or within 6 months after the first malignancy, and metachronous, if 
developed after 6 months [1]. It was firstly reported by Billroth [2].  
Case presentation 
A 67 years old heavy smoker male patient presented with recurrent hematuria, dysuria, hesitancy and 
generalized bony pain for a period four months which were gradual onset and progressive course. 
Magnetic Resonance Imaging (MRI) of the pelvis revealed posterior urinary bladder wall polyp and 
heterogeneous prostatic mass (figure1; a, b). Bone scan showed extensive bone metastasis. At the level of 
routine laboratory tests, no alterations of the principal biochemical parameters were found; only PSA had 
a value of 87ng/dl and serum alkaline phosphatase was 1285 u/l.  
  
Figure1a Axial MRI T2WI: posterior urinary bladder wall polyp           Figure1b axial MRI T2WI: heterogeneous prostatic mass. 
Biopsies were taken from both prostatic lobes (imaging guided) and from bladder mass through 
transurethral resection (TUR). Histopathological examination revealed synchronous papillary urothelial 
bladder carcinoma, low grade without vascular or lymphatic invasion, and prostatic adenocarcinoma; 
Gleason score grade 4+4 = score of 8, involving 60% of needle core biopsy with perineural invasion is 
present (figure 2; a, b). 
 
  
Figure 2a urinary bladder: carcinoma, M 12.6 X, H & E.              Figure 2b Prostate: Adenocarcinoma, M 2.52 X H&E 
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We diagnosed the case as stage I non invasive bladder urothelial carcinoma, low grade which treated by 
TUR and stage IV prostatic adenocarcinoma which started on LHRH agonist and Zoledronic acid. After 
nine months of follow up with subjective and objective improvement in the form of normalization in 
alkaline phosphatase and PSA levels), there was painless neck mass of gradual onset and progressive 
course.  
Computed tomography scan of the neck showed multiple bilateral thyroid nodules (right lobe 
measuring 2.2 x 3.6 x 2cm and the left lobe measuring 1.8 x 4 x 2cm), subcentimetric deep cervical and 
supraclavicular lymphadenopathy (figure 3). 
Fine needle aspiration was taken from both nodules with histopathology evaluation revealed bilateral 
multifocal thyroid carcinoma with lymphovascular invasion and eleven out of twenty lymph nodes were 
positive for carcinoma with extra capsular extension (figure 4).The patient was subjected to total 
thyrodectomy with neck dissection. Post operative period passed smoothly without serious complication. 
 
  
Figure 3 Axial CT neck; bilateral thyroid soft tissue nodules.                      Figure 4 Thyroid papillary carcinoma, M 6.3X, H &E. 
Discussion 
MPCs are defined as two or more malignancies in a single individual without any relationship between 
them. 
Warren and Gates [3] emphasized that each tumor must afford a picture of malignancy, each must be 
distinct, and the probability of one being a metastasis of the other must be ruled out. They can be 
classified into four types;1- multicentric, if the two distinct carcinoma arise in the same organ or tissue; 2- 
systemic, if they arise on anatomically or functionally allied organs of the same system, 3- paired organs, 
as in the breasts, and 4- random, if they occur as a co-incidental or accidental association in unrelated 
sites [4]. 
Factors that will continue to drive the increase in the number of survivors include the improvements in 
cancer detection in early stage, advances in treatment and treatments outcome. 
In the last three decades, cancer has been transformed from a fatal disease to one in which the majority 
of people diagnosed with cancer receive highly effective treatments that result in either cure or long-term 
survivorship which increase the risk of MPCs development. This is explained by several reasons, 
including genetic predisposition, environmental exposure, exposure to carcinogenic cancer therapies (i.e., 
iatrogenic risks associated with chemotherapy, radiotherapy and/or hormonal therapy), life-style factors, 
such as smoking, and, perhaps most importantly, aging. 
There is wide range in the frequency rate of MPCs ranged between 0.7% and 14.5%1[5] which can be 
explained by many factors [6-8]:  
a. The majority of published works on them are case reports. 
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b. Most reports lacked unified definition of MPC. 
c. It is not clear whether this range referred to the number of patients with MPCs or MPCs in 
studied series or it referred to synchronous, metachronous or both. 
d. There are very few studies on MPC patients with many limited points as the lower frequency rate, 
lacked age, gender distribution, time of occurrence and commonest anatomic site. 
e. The rate at the upper end is influenced by reports based on risk factors and mathematical 
formulation. 
f. The rate at the lower end reflects their rarity. 
Prostate cancer is the most prevalent cancer and the second leading cause of death in western male 
population. Bladder cancer is the fourth in prevalence of cancer in the same population [9]. Over 90% of 
prostate cancers are adenocarcinomas [10], among bladder tumors, 90% are urothelial carcinomas [11], as 
in our case.The presence of bladder and prostate carcinomas in the same patient is not a rare event [12].  
In terms of etiopathogenesis, several hypotheses have been issued. One of them refers to the fact that 
the genitourinary region is under the influence of the same carcinogenic stimuli. Another hypothesis 
refers to the fact that the first malignant tumor affects the adjacent environment, predisposing to the 
development of second malignancies [13]. On the other hand, the mean age of prostate cancer is 65 years 
and prostate cancer incidence increases exponentially with each decade of age. Most bladder cancers 
occur after 50 years of age. Although many factors have been incriminated in its etiopathogenesis, the 
only factor present in this case was smoking.  
Although bladder and prostate carcinoma can coexist in the same individual frequently enough, the rare 
event is the appearance of a third malignancy.  
There are two cases reported with three primary tumors including bladder and prostate; The first tumor 
reported by Rovinescu et al [14] was a clear cell carcinoma of the kidney, which was followed by a 
transitional cell carcinoma of the bladder and then by a distinct adenocarcinoma of the prostate. The 
second one in 2003, Satoh et al [15] also reported the same combination of multiple primary malignancies 
in a patient. Our case is the first one of an individual having these two primary malignancies of the 
urogenital system and another tumor of the thyroid gland.  
The possibility that MPCs exist must always be considered during pretreatment evaluation. Screening 
procedures are especially useful for the early detection of associated tumors, preferably before clinical 
manifestations occur. There is some evidence that screening will improve outcomes among patients who 
may develop second malignancies, although the data are limited. The optimal screening modalities and 
strategies to reduce mortality from second malignancies remain to be defined for most tumor sites. The 
early diagnosis of secondary malignancies should not be neglected in patients treated for a primary 
malignancy, especially when the long clinical period before the diagnosis of subsequent tumors is taken 
into consideration. With careful monitoring, secondary tumors can be detected earlier, and, with 
appropriate intervention, might be better managed, without compromising survival. 
Conclusion 
The diagnosis of cancer should not exclude the existence of other concomitant malignancy; especially in 
patients more than the sixth decade of age. Moreover, the combination of the three different tumors 
(bladder, prostate and papillary) in one patient, to the best of our knowledge, has never been reported 
before. 
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